VELCADE 1 mg powder for solution for injection
Sponsors
Celgene Corp., Cancer Trials Ireland, Medical University Of Warsaw
Conditions
Light chain amyloidosis (AL amyloidosis) is an incurable plasma cell neoplasm and the most common among a heterogeneous group of over 30 rare and ultra-rare diseases known as amyloidoses. In AL amyloidosis the deposition of amyloid fibrils resulting from misfolded immunoglobulin light chains leads to end-stage failure of the affected organsNewly diagnosed Multiple MyelomaRelapsed or Refractory Multiple Myeloma (RRMM)a 3-week treatment with sargramostim resulted in improved cognitive functiona relationship between high levels of GM-CSF in the synovial fluid and a lower risk of developing Alzheimer's diseasebased on the results of the ANDROMEDA phase III clinical trialclinical trials with opsonizing antibodies are ongoingcyclophosphamide and dexamethasone. The recombinant granulocyte macrophage colony stimulating factor (GM-CSF) sargramostim will be used in this study with the D-VCD regimen. Currently
Phase 2
Isa-RVD Study: Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Active, not recruitingCTIS2024-512749-18-00
Start: 2022-03-03Target: 52Updated: 2025-06-03
Phase II, Multicenter Study to Assess Safety and Efficacy
of Combination of Sargramostim with D-VCd Therapy
(Daratumumab, Cyclophosphamide, Bortezomib,
Dexamethasone) in Untreated Patients with Light
Chain Amyloidosis
Active, not recruitingCTIS2024-518658-18-00
Start: 2023-07-26Target: 20Updated: 2025-09-11